SC1011 for idiopathic pulmonary fibrosis (IPF)
Part of Lungs & breathing clinical trials.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with IPF within the last 5 years.
- Your lung function tests must show a certain level of severity (DLCO between 30% and 90% of normal, and FVC at least 50% of normal).
- You must not have other lung diseases like asthma or COPD, or a history of heart or lung problems getting worse in the past 6 months.
- You must not be on other IPF treatments, including experimental drugs or immunosuppressants.
- You cannot be awaiting a lung transplant or expected to need one within the next year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.